Cerebrospinal protein tau is elevated in early Alzheimer's disease

Riemenschneider, Matthias; Buch, Katharina; Schmolke, Michael; Kurz, Alexander; Guder, W.G.

doi:10.1016/0304-3940(96)12810-x

Cited by 77 publications

(24 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Others have reported a significant elevation of tau with increasing functional assessment staging scores [14,29]. These conflicting results might be due to differences in age and degree of dementia in the studied groups, since some results indicate that the relation between CSF tau and clinical progression of AD does not fit into linear regression models but rather increases in early stages and declines in severe AD [10,11,22,29].…”

Section: Discussionmentioning

confidence: 70%

See 1 more Smart Citation

Cerebrospinal Fluid Tau Levels Increase with Age in Healthy Individuals

Blomberg

Jensen²,

Basun³

et al. 2001

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Cerebrospinal fluid (CSF) tau is a promising biochemical ante-mortem marker for Alzheimer’s disease (AD). Levels are increased in AD compared to other dementias, neurological diseases and healthy controls. An age-related decrease in both soluble tau and tau bound to paired helical filaments has been shown in brains from non-demented subjects. To study tau levels in normal ageing, we investigated CSF in 29 healthy individuals aged 45–80 years. A statistically significant increase in CSF tau with increasing age was found which might be caused by neuronal loss during normal ageing and redistribution of soluble tau from the brain into CSF. We could not demonstrate any influence by the APOE genotype, though larger populations have to be investigated to confirm this result. In conclusion, we found an age-dependent increase in CSF tau in healthy individuals. We emphasise the importance of establishing an age-dependent interval of CSF tau in non-demented subjects.

show abstract

Section: Discussionmentioning

confidence: 70%

“…Regarding the MMSE, results are contradictory. Some groups have shown a correlation between high tau and low MMSE scores in AD [4,6,14] while others did not [2,5,8,10,11,16,22,25]. The MMSE is a tool for estimation of cognitive status.…”

Section: Discussionmentioning

confidence: 99%

Cerebrospinal Fluid Tau Levels Increase with Age in Healthy Individuals

Blomberg

Jensen²,

Basun³

et al. 2001

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

show abstract

“…So, the use of these new biomarkers could lead to novel diagnostics and therapeutics approaches for Alzheimer's diseases. -Tau proteins Increase of T-tau CSF levels was found in AD patients as well as MCI patients who will develop later an AD (Riemenschneider, Buch et al 1996;Andreasen, Minthon et al 2001;Riemenschneider, Lautenschlager et al 2002;Hansson, Zetterberg et al 2006). Measurement of T-tau levels with ELISA test (Innotest hTau Ag, Innogenetics) reveal concentrations between 150 pg/mL and 450 pg/mL in control subjects and between 300 and 1100 pg/mL in AD patients (Riemenschneider, Lautenschlager et al 2002;Grossman, Farmer et al 2005).…”

Section: Which Csf Biochemical Markers Might Allow Us To Detect Alzhementioning

confidence: 99%

Alzheimer’s Diseases: Towards Biomarkers for an Early Diagnosis

Elmoualij¹,

Dupiereux-Fettweis²,

Seguin³

et al. 2011

The Clinical Spectrum of Alzheimer's Disease -the Charge Toward Comprehensive Diagnostic and Therapeutic Strategies

View full text Add to dashboard Cite

“…Indeed, CSF tau was increased in most AD patients with mild disease: in groups with MMSE scores higher than 20 (n=22 and 205, respectively) 39,59 or between 25 and 28 (n=11). 60 Moreover, a combination of decreased CSF Ab 42 and increased tau was observed in 14 out of 16 MCI patients with MMSE scores 426 and progression to AD during follow-up investigations. 41 Furthermore, using a cut-o¡ level established in a previous study, 24 sensitivity for the diagnosis of MCI by using the combination of tau and Ab 42 was 75%.…”

Section: Mild Cognitive Impairmentmentioning

confidence: 99%

Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases

Verbeek¹,

Jong²,

Kremer³

2003

Ann Clin Biochem

View full text Add to dashboard Cite

Neurodegenerative disorders have traditionally been classi ed according to clinical criteria, e.g. as dementia syndromes (the best known is Alzheimer's disease) or as movement disorders (e.g. Parkinson's disease). Another subdivision is based on recent insights into the respective pathogenetic mechanisms, leading to the recognition of so-called tauopathies and a-synucleinopathies. It is this increased knowledge of the underlying (neuro)pathological mechanisms that has sparked interest in studies aimed at the identi cation of disease-speci c biomarkers in cerebrospinal uid (CSF) for this eld of neurological disorders. This review deals with the recent progress that has been made in identi cation, quanti cation and subsequent validation of brain-speci c proteins in CSF for the diagnosis of various neurodegenerative disorders. Development of disease-speci c CSF biomarkers will undoubtedly add to the process of differential diagnosis early in the course of the disease.

show abstract

Cerebrospinal protein tau is elevated in early Alzheimer's disease

Cited by 77 publications

References 8 publications

Cerebrospinal Fluid Tau Levels Increase with Age in Healthy Individuals

Cerebrospinal Fluid Tau Levels Increase with Age in Healthy Individuals

Alzheimer’s Diseases: Towards Biomarkers for an Early Diagnosis

Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases

Contact Info

Product

Resources

About